PL3679042T3 - Pochodne imidazo[1,5-a]pirazyny jako inhibitory PI3Kdelta - Google Patents
Pochodne imidazo[1,5-a]pirazyny jako inhibitory PI3KdeltaInfo
- Publication number
- PL3679042T3 PL3679042T3 PL18853233.7T PL18853233T PL3679042T3 PL 3679042 T3 PL3679042 T3 PL 3679042T3 PL 18853233 T PL18853233 T PL 18853233T PL 3679042 T3 PL3679042 T3 PL 3679042T3
- Authority
- PL
- Poland
- Prior art keywords
- imidazo
- pyrazine derivatives
- pi3kdelta
- inhibitors
- pi3kdelta inhibitors
- Prior art date
Links
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 title 1
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 title 1
- MIFJMFOVENWQDP-UHFFFAOYSA-N imidazo[1,5-a]pyrazine Chemical class C1=CN=CC2=CN=CN21 MIFJMFOVENWQDP-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017101058 | 2017-09-08 | ||
| CN2017119373 | 2017-12-28 | ||
| CN2018086555 | 2018-05-11 | ||
| PCT/CN2018/104559 WO2019047915A1 (en) | 2017-09-08 | 2018-09-07 | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3679042T3 true PL3679042T3 (pl) | 2023-09-04 |
Family
ID=65633578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18853233.7T PL3679042T3 (pl) | 2017-09-08 | 2018-09-07 | Pochodne imidazo[1,5-a]pirazyny jako inhibitory PI3Kdelta |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11220506B2 (pl) |
| EP (2) | EP3679042B1 (pl) |
| JP (1) | JP7128264B2 (pl) |
| KR (1) | KR20200052297A (pl) |
| CN (2) | CN111704615B (pl) |
| AU (2) | AU2018328569B2 (pl) |
| BR (1) | BR112020004500A2 (pl) |
| CA (1) | CA3072842A1 (pl) |
| DK (1) | DK3679042T3 (pl) |
| ES (1) | ES2944658T3 (pl) |
| FI (1) | FI3679042T3 (pl) |
| HU (1) | HUE061898T2 (pl) |
| IL (1) | IL272988B (pl) |
| MX (1) | MX2020002630A (pl) |
| NZ (1) | NZ761680A (pl) |
| PL (1) | PL3679042T3 (pl) |
| PT (1) | PT3679042T (pl) |
| SG (1) | SG11202001286SA (pl) |
| TW (2) | TWI817956B (pl) |
| WO (1) | WO2019047915A1 (pl) |
| ZA (1) | ZA202000875B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI762534B (zh) | 2016-12-07 | 2022-05-01 | 英屬開曼群島商百濟神州有限公司 | 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物 |
| TWI817956B (zh) | 2017-09-08 | 2023-10-11 | 英屬開曼群島商百濟神州有限公司 | 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑 |
| WO2021098777A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| JP2024521763A (ja) * | 2021-05-27 | 2024-06-04 | ベイジーン スウィッツァーランド ゲーエムベーハー | Ｐｉ３ｋデルタ阻害剤の塩、その結晶形態、調製方法、及び使用 |
| WO2023040810A1 (en) * | 2021-09-14 | 2023-03-23 | Beigene, Ltd. | Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005089352A (ja) * | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| US7459554B2 (en) * | 2003-10-15 | 2008-12-02 | Osi Pharmaceuticals, Inc. | Imidazopyrazine tyrosine kinase inhibitors |
| JP5156644B2 (ja) * | 2006-01-25 | 2013-03-06 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | 不飽和ｍＴＯＲ阻害剤 |
| RU2011140238A (ru) | 2009-04-15 | 2013-05-20 | Астразенека Аб | Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера |
| JP5805623B2 (ja) | 2009-04-16 | 2015-11-04 | フンダシオン セントロ ナシオナル デ インベスティガシオネス オンコロヒカス カルロス ザ サードＦｕｎｄａｃｉｏｎ Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ Ｃａｒｌｏｓ ＩＩＩ | キナーゼ阻害剤として使用するためのイミダゾピラジン類 |
| CN103476767B (zh) * | 2011-02-09 | 2015-06-10 | 弗·哈夫曼-拉罗切有限公司 | 作为pi3激酶抑制剂的杂环化合物 |
| US9260435B2 (en) * | 2012-01-10 | 2016-02-16 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyrazines as Akt kinase inhibitors |
| KR102229478B1 (ko) * | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| TWI657090B (zh) * | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
| RU2019134551A (ru) | 2013-05-30 | 2019-11-22 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| EP3057970A1 (en) * | 2013-10-18 | 2016-08-24 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| RS62713B1 (sr) * | 2014-08-11 | 2022-01-31 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora |
| AR102220A1 (es) * | 2015-10-08 | 2017-02-15 | Incyte Corp | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 |
| CA3025594C (en) * | 2016-06-16 | 2024-06-18 | Janssen Pharmaceutica Nv | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors |
| TWI762534B (zh) * | 2016-12-07 | 2022-05-01 | 英屬開曼群島商百濟神州有限公司 | 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物 |
| TWI817956B (zh) | 2017-09-08 | 2023-10-11 | 英屬開曼群島商百濟神州有限公司 | 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑 |
-
2018
- 2018-09-07 TW TW107131522A patent/TWI817956B/zh not_active IP Right Cessation
- 2018-09-07 CA CA3072842A patent/CA3072842A1/en active Pending
- 2018-09-07 WO PCT/CN2018/104559 patent/WO2019047915A1/en not_active Ceased
- 2018-09-07 BR BR112020004500-4A patent/BR112020004500A2/pt not_active Application Discontinuation
- 2018-09-07 CN CN202010273331.8A patent/CN111704615B/zh active Active
- 2018-09-07 SG SG11202001286SA patent/SG11202001286SA/en unknown
- 2018-09-07 TW TW111147323A patent/TW202336010A/zh unknown
- 2018-09-07 FI FIEP18853233.7T patent/FI3679042T3/fi active
- 2018-09-07 EP EP18853233.7A patent/EP3679042B1/en active Active
- 2018-09-07 DK DK18853233.7T patent/DK3679042T3/da active
- 2018-09-07 MX MX2020002630A patent/MX2020002630A/es unknown
- 2018-09-07 AU AU2018328569A patent/AU2018328569B2/en not_active Ceased
- 2018-09-07 HU HUE18853233A patent/HUE061898T2/hu unknown
- 2018-09-07 IL IL272988A patent/IL272988B/en unknown
- 2018-09-07 ES ES18853233T patent/ES2944658T3/es active Active
- 2018-09-07 PL PL18853233.7T patent/PL3679042T3/pl unknown
- 2018-09-07 US US16/643,040 patent/US11220506B2/en active Active
- 2018-09-07 NZ NZ761680A patent/NZ761680A/en not_active IP Right Cessation
- 2018-09-07 JP JP2020513700A patent/JP7128264B2/ja active Active
- 2018-09-07 KR KR1020207007386A patent/KR20200052297A/ko active Pending
- 2018-09-07 PT PT188532337T patent/PT3679042T/pt unknown
- 2018-09-07 EP EP23152036.2A patent/EP4219502A1/en not_active Withdrawn
- 2018-09-07 CN CN201880057835.7A patent/CN111051312A/zh active Pending
-
2020
- 2020-02-11 ZA ZA2020/00875A patent/ZA202000875B/en unknown
-
2021
- 2021-11-23 US US17/533,442 patent/US11905294B2/en active Active
-
2023
- 2023-10-25 AU AU2023254925A patent/AU2023254925A1/en active Pending
-
2024
- 2024-01-11 US US18/410,925 patent/US20240150361A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| IL260923B (en) | History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors | |
| IL265918A (en) | Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors | |
| ZA201800771B (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| IL290419A (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
| ZA201802842B (en) | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound | |
| IL252656A0 (en) | 4- and 6-substituted pyrazolo[5,1-a]pyrazines as Janus kinase inhibitors | |
| IL247947B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors | |
| IL272988A (en) | Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors | |
| IL247948B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors | |
| IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
| HK40065699A (zh) | 经取代的吡唑并[1 ,5-a]吡啶化合物作为ret激酶抑制剂 | |
| HK40065699B (zh) | 经取代的吡唑并[1 ,5-a]吡啶化合物作为ret激酶抑制剂 | |
| HK40035586A (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
| HK1238236A1 (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors |